[Prognostic factors in breast cancer patients].
Roisman
I
I
Peretz
T
T
Reznick
A Z
AZ
Lifshitz
I
I
Bitterman
A
A
Fares
F
F
Toledano
H
H
Barzilay
A
A
Durst
A L
AL
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D002402:Cathepsin D / Q000032:analysis; D002882:Chromosomes, Human, Pair 13; D002886:Chromosomes, Human, Pair 17; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005346:Fibroblast Growth Factors / Q000032:analysis; D006801:Humans; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D017481:Receptors, Somatostatin / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis
D014408:Biomarkers, Tumor; D002402:Cathepsin D; D066246:ErbB Receptors; D005346:Fibroblast Growth Factors; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017481:Receptors, Somatostatin; D016159:Tumor Suppressor Protein p53; D014568:Urokinase-Type Plasminogen Activator